KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Short-term Investments (2016 - 2023)

Historic Short-term Investments for Amgen (AMGN) over the last 15 years, with Q1 2023 value amounting to $1.0 million.

  • Amgen's Short-term Investments fell 9375.0% to $1.0 million in Q1 2023 from the same period last year, while for Mar 2023 it was $1.0 million, marking a year-over-year decrease of 9375.0%. This contributed to the annual value of $1.7 billion for FY2022, which is 339166.67% up from last year.
  • Amgen's Short-term Investments amounted to $1.0 million in Q1 2023, which was down 9375.0% from $1.7 billion recorded in Q4 2022.
  • Amgen's Short-term Investments' 5-year high stood at $9.1 billion during Q3 2019, with a 5-year trough of $1.0 million in Q1 2023.
  • Over the past 5 years, Amgen's median Short-term Investments value was $2.0 billion (recorded in 2022), while the average stood at $2.9 billion.
  • Over the last 5 years, Amgen's Short-term Investments had its largest YoY gain of 339166.67% in 2022, and its largest YoY loss of 9964.08% in 2022.
  • Over the past 5 years, Amgen's Short-term Investments (Quarter) stood at $2.9 billion in 2019, then surged by 52.44% to $4.4 billion in 2020, then crashed by 98.9% to $48.0 million in 2021, then surged by 3391.67% to $1.7 billion in 2022, then plummeted by 99.94% to $1.0 million in 2023.
  • Its Short-term Investments stands at $1.0 million for Q1 2023, versus $1.7 billion for Q4 2022 and $2.0 billion for Q3 2022.